Terms of the deal have not been disclosed.
Under the deal, Roche will acquire the products associated with the patent-protected Heat Elution technology for nucleic acid purification of multiple sample types, including challenging formalin-fixed paraffin-embedded (FFPE) tumor samples.
Lumora CEO Laurence Tisi said: "An important bottleneck in sequencing workflow is nucleic acid extraction. Heat Elution technology significantly simplifies extraction and is simple to automate."
Roche intends to integrate the acquired technology into its sequencing workflow solution.
Lumora’s technology can be used to process a wide variety of sample types, including whole blood, fecal matter, sputum, FFPE tissue and buccal swabs.
Roche Tissue Diagnostics and Roche Sequencing Unit head Dan Zabrowski said: "Lumora’s Heat Elution technology can be integrated to an automated sequencing workflow, which makes it an ideal fit for Roche’s sequencing vision of a sample-in-results-out workflow."
